Searched for
DRL EARNINGS NEWS
'Factually incorrect': Dr Reddy's denies 25% workforce cost reduction claimDr. Reddy's Laboratories has refuted a media report alleging a significant workforce cost reduction initiative. The report claimed the comp...- Dr Reddy’s slashing jobs to cut costs by 25%, asks several Rs 1 crore+ earners to resign; co denies reportDr. Reddy's Laboratories is implementing cost-cutting measures, aiming to reduce manpower expenses by 25%. High-salaried employees, includi...
- Will Nifty make up for Friday’s loss? 6 factors to track this weekNifty ended higher last week with banking sector influence. Positive sectors, except IT. Rising VIX hints at volatility. FPI flows, US bond...
- Dr Reddy's Q3 Results: Net profit rises 11% YoY to Rs 1,379 crore, meets estimatesDRL Q3 Results: The profit was slightly above the ET Now poll estimate of Rs 1,337 crore. Revenue from operations increased 7% year-on-year...
- DRL, Cipla can outperform in the near term: Hemang JaniI think maybe because of this news you might see some action in the RBL Bank but I do not really think that there is a case for too much of...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Dr Reddy's Labs Q4 Results: PAT sees nine-fold jump to Rs 960 crore, dividend declared at Rs 40/shareIndian pharmaceutical major Dr Reddy's Laboratories reports a whopping 890% YoY growth in net profit. Revenue from operations stood at Rs 5...
- Sensex snaps 3-day winning run on selling in IT packIndia’s June inflation data is expected to remain in line with May’s inflation rate of 7.04 per cent. Meanwhile, the US inflation data due ...
- Sensex, Nifty gain for 3rd week in a row as inflation concerns ebbThe 30-share pack Sensex rose for the third day as it advanced 303 points or 0.56 per cent to 54,482. Its broader peer, Nifty50 added 88 po...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- Covid 2.0 may herald the comeback of pharma stocksDevang Mehta, head of equity advisory at Centrum India, is bullish on pharma stocks.
- It is ridiculous to build DRL earnings expectations based on Russia vaccine tieup: Sandip Sabharwal‘ The Russian vaccine is not an approved vaccine and hardly any trials have taken place.’
- DRL Q1 profit surges 45% YoY to Rs 663 crore; margins shrink 400 bpsAnalysts in an ET Now poll had anticipated Rs 481 crore profit.
- Can USFDA all-clear for Duvvada earn Dr Reddy’s stock a rerating?The Duvvada news has lifted a big overhang from the stock, said Edelweiss Securities.
- IIFL’s Abhimanyu Sofat is bullish on this smallcap, here's why“We will continue to be overweight on IT sector going forward”
- Five triggers that changed your market while you were sleepingA June rate hike by the US Fed rate is back on the table, which means trouble ahead for the Sensex, which some say will hardly move anywher...
- USFDA becoming dreaded word in Dalal Street; pharma companies need to keep Street in the loopThe stock of drug major Dr Reddy’s Labs (DRL) crashed 22% in the last three days, swiftly eroding the gains made over the last five months.
- Positive on API manufacturers, prefer Sequent Scientific: Prakash DiwanThe buying of warrants by the promoter group of Sequent Scientific reflects their confidence in the business, points out Diwan.
- Dr Reddy's Laboratories may file new drug applications with FDA within yearChief Operating Officer and Member of the Management Council, DRL, Abhijit Mukherjee said one drug is currently in the late phase-III .
- Why pharma is a good bet: 3 stocks to watch out forThe pharma stocks are not participating in the current market rally, but their existing valuations offer an attractive entry point for long...
Load More
